DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand.
$1.26-23.64%
报价 2026-11-13
市值
$12.3M
EV
$49.2M
PE (TTM)
3.5x
预期 PE (FY2026)
–
52 周区间距高点 -91.0%
$1.26$14.00
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| DRIODarioHealth Corp. | $12.3M | -23.6% | +17.4% | 56.1% | 3.5x | – | – | |
| ABSIAbsci Corporation | $1.46B | -7.5% | +2.8% | -255.9% | – | – | – | |
| INNVInnovAge Holding Corp. | $1.29B | +0.7% | +11.4% | 17.7% | 165.1x | 30.4x | 17.5x | |
| VSTMVerastem, Inc. | $1.03B | -3.1% | +264.2% | 86.7% | – | – | – | |
| FLGTFulgent Genetics, Inc. | $689M | -0.8% | +3.3% | 33.8% | – | – | – | |
| PACBPacific Biosciences of California, Inc. | $612M | -0.5% | -0.6% | 36% | – | – | – | |
| MYGNMyriad Genetics, Inc. | $542.9M | -0.4% | -4.7% | 68.8% | – | – | – | |
| RGNXREGENXBIO Inc. | $505.2M | -4.9% | -17.8% | 87.5% | – | – | – | |
| OFIXOrthofix Medical Inc. | $292.2M | +3.3% | +3.1% | 69.6% | – | 5.7x | – | |
| 同行中位数 | – | – | +2.9% | 52.4% | 165.1x | 18.0x | 17.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。